Clinical Trials

Psychedelic Research Drug Development Nasal COVID-19 Vaccine Cancer Immunotherapy Gene Mutation Obesity Treatment Phase 3 Studies Human Trials Safety Testing Cancer Treatment Research and Development Immunotherapy Autoimmune Diseases Health Innovations Drug Development Stages Gene Therapy Research Innovation Cancer Research Trial Design Metabolic Diseases Machine Learning Antibodies Phase 2 and Phase 3 Trials Phase 2 Trials Phase 3 Trials Medical Research Drug Approval

11 ARTICLES

6d ago

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

The all-cash $77-per-share tender offer is intended to add FB102, a first-in-class anti-CD122 antibody, to broaden argenx’s immunology pipeline beyond Vyvgart.

6 ARTICLES

3mo ago

Senhwa Signs MOU With GEM for Up to NT$500 Million to Speed AI-Driven Cancer R&D

4 ARTICLES

4mo ago

DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

9 ARTICLES

4mo ago

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

4 ARTICLES

4mo ago

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

5 ARTICLES

7mo ago

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

7 ARTICLES

9mo ago

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

7 ARTICLES

9mo ago

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

6 ARTICLES

9mo ago

First Human Trial Finds Enteral Ventilation Procedure Tolerable in Healthy Volunteers

5 ARTICLES

9mo ago

Samsung Invests $110 Million in Grail to Bring Galleri Cancer Test to Asia

7 ARTICLES

11mo ago

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion

3 ARTICLES

last yr.

Clinical Trials

Argenx Agrees to Buy Forte Biosciences for $2.2 Billion

Senhwa Signs MOU With GEM for Up to NT$500 Million to Speed AI-Driven Cancer R&D

DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

First Human Trial Finds Enteral Ventilation Procedure Tolerable in Healthy Volunteers

Samsung Invests $110 Million in Grail to Bring Galleri Cancer Test to Asia

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy